Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/28896
Title: Durable Efficacy and Safety With Alemtuzumab in CARE-MS I Patients Switching From SC IFNB-1a: 5-Year Follow-up (TOPAZ Study)
Authors: Steingo, Brian
Oreja-Guevara, Celia
Alroughani, Raed
Brassat, David
Boyko, Alexey N.
McCombe, Pamela
VAN WIJMEERSCH, Bart 
Margolin, David H.
Melanson, Maria
Daizadeh, Nadia
Rodriguez, Claudio E.
Vermersch, Patrick
Issue Date: 2018
Publisher: LIPPINCOTT WILLIAMS & WILKINS
Source: NEUROLOGY, 90(15) (Art N° P6.376)
Notes: [Steingo, Brian] Ft Lauderdale Multiple Sclerosis Ctr, Ft Lauderdale, FL USA. [Oreja-Guevara, Celia] Univ Hosp San Carlos, Madrid, Spain. [Alroughani, Raed] Amiri Hosp, Sharq, Kuwait. [Brassat, David] Univ Toulouse, Purpan Hosp, Toulouse, France. [Brassat, David] Univ Toulouse, Mixed Unit Res 1043, Toulouse, France. [Boyko, Alexey N.] Pirogov Russian Natl Res Univ, Moscow, Russia. [Boyko, Alexey N.] Usupov Hosp, Demyelinating Dis Ctr, Moscow, Russia. [McCombe, Pamela] Univ Queensland, Brisbane, Qld, Australia. [Van Wijmeersch, Bart] Hasselt Univ, Rehabil, Hasselt, Belgium. [Van Wijmeersch, Bart] Hasselt Univ, MS Ctr Overpelt, BIOMED, Hasselt, Belgium. [Margolin, David H.; Melanson, Maria; Daizadeh, Nadia; Rodriguez, Claudio E.] Sanofi, Cambridge, MA USA. [Vermersch, Patrick] Univ Lille, Lille, France.
Document URI: http://hdl.handle.net/1942/28896
ISSN: 0028-3878
e-ISSN: 1526-632X
ISI #: 000453090805102
Rights: 2018, American Academy of Neurology
Category: M
Type: Journal Contribution
Appears in Collections:Research publications

Files in This Item:
File Description SizeFormat 
Schmidtea mediterranea as an alternative model to predict carcinogenicity via its stem cell responses _ Elsevier Enhanced Reader.pdf
  Restricted Access
Published version - Experiment data readings712.7 kBAdobe PDFView/Open    Request a copy
Show full item record

Page view(s)

16
checked on May 28, 2022

Download(s)

6
checked on May 28, 2022

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.